CTC Alternative Strategies’s ProKidney PROK Stock Holding History

CTC Alternative Strategies’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,453	Closed	-$24.1K	–	135
2026 Q1	$24.1K	Buy	+13,453	New	+$28.5K	0.05%	90

Other funds holding PROK

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CTC Alternative Strategies's PROK Position: Q2 2026 in Review

CTC Alternative Strategies sold out of ProKidney (PROK) in Q2 2026, closing a stake of 13,453 shares — an estimated $24.1K sold.

CTC Alternative Strategies first reported a position in PROK in Q1 2026 and held it in 1 quarter. The position peaked at $24.1K in Q1 2026. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

CTC Alternative Strategies reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
CTC Alternative Strategies sold 13,453 ProKidney shares in Q2 2026, an estimated $24.1K.
CTC Alternative Strategies first reported a position in ProKidney in Q1 2026 and held it in 1 quarter.
CTC Alternative Strategies's ProKidney position peaked at $24.1K in Q1 2026.
71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.